top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Antiviral Agents
Antiviral Agents
Autore Adamson Catherine
Pubbl/distr/stampa Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
Descrizione fisica 1 electronic resource (386 p.)
Soggetto topico Research & information: general
Biology, life sciences
Soggetto non controllato Zika virus
nucleoside analogues
antiviral agents
NS5
prodrugs
ProTides
neural stem cells
RNA-dependent RNA polymerase
cytomegalovirus
latent infection
TALEN
Surveyor nuclease mutation detection assay
ie-1 gene
quantitative real-time PCR
Epstein-Barr virus
herpes viruses
lytic gene expression
Burkitt lymphoma cells
clozapine
antipsychotic drug
antiviral drug
enteroviruses
coxsackievirus B4
persistent infection
fluoxetine
resistance
mutations
herpes B virus
macacine herpesvirus-1
genistein
flavonoids
acyclovir
ganciclovir
Plantago asiatica
Clerodendrum trichotomum
RSV
therapeutic effects
acteoside
human antimicrobial peptides
antiviral strategies
defensins
cathelicidins
hepcidins
transferrins
influenza A virus
brevilin A
antiviral
sesquiterpene lactone
replication
PRRSV
polyethylenimine
PEI
virion internalization
endocytosis
HIV
pediatrics
Ethiopia
pre-treatment drug resistance
combination antiretroviral therapy (cART)
dried plasma spots
dried blood spots
sphingolipids
glycosphingolipids
viruses
lipid biosynthesis
flavivirus
Japanese encephalitis virus
furin inhibitor
precursor membrane protein
measles virus
central nervous system
tropism
treatments
porcine reproductive and respiratory syndrome virus
ginsenoside Rg1
antiviral activity
pro-inflammatory factor
NF-κB signaling pathway
acute/latent infection
congenital infection
antiviral agent
therapeutic strategies
nucleic acid-based therapeutic approach
HCMV vaccine
adoptive cell therapy
Rev response element
chemical footprinting
SHAPE
drug discovery
branched peptides
herpesvirus
immediate-early
IE1
IE2
ribozyme
RNA interference
CRISPR/Cas
small molecule
orthohantavirus
phenyl-benzotriazoles
C-FRA
Porcine circovirus type 2
epigallocatechin gallate
heparan sulfate
antiviral effect
virus attachment
microvirin
lectin
human immunodeficiency virus
hepatitis C virus
antiviral inhibitor
non-immunogenic
viral entry
protein drugs
LUMS1
oleanane-type derivatives
influenza A virus (IAV)
virus entry inhibitors
hemagglutinin (HA)
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557448703321
Adamson Catherine  
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Targeting STAT3 and STAT5 in Cancer
Targeting STAT3 and STAT5 in Cancer
Autore Moriggl Richard
Pubbl/distr/stampa Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
Descrizione fisica 1 electronic resource (578 p.)
Soggetto topico Research & information: general
Biology, life sciences
Soggetto non controllato multiple myeloma
STAT3
S3I-1757
nanoparticle
CD38
siRNA/RNAi
polyethylenimine
PEI
lipopolyplex
siRNA delivery
glioma
glioblastoma
STAT5
AKT
ERK1/2
prolactin
androgens
prostate cancer
knockout
escape mechanisms
stem/progenitor cells
cell hierarchy
cancer
CD4+ T cells
CD8+ T cells
myeloid cells
immune check point
hepatitis C virus (HCV)
cirrhosis
hepatocellular carcinoma (HCC)
endoplasmic reticulum (ER) stress
oxidative stress (OS)
unfolded protein response (UPR)
microRNA-122 (miR-122)
nuclear factor erythroid 2-related factor 2 (NRF2)
signal transducer and activator of transcription 3 (STAT3)
hepatocyte nuclear factor 4 alpha (HNF4A)
solid cancers
cell cycle
apoptosis
inflammation
mitochondria
stemness
tumor suppression
melanoma
autoimmune disease
immunotherapy
tumor-immune cell interactions
breast cancer
PD-L1
M2 macrophages
NK cells
STAT3 inhibitor XIII
hedging
transaction costs
dynamic programming
risk management
post-decision state variable
cancer progression
cancer-stem cell
cytokine
therapy resistance
metastasis
immunosuppression
tumor microenvironment
proliferation
tyrosine kinase 2
JAK family of protein tyrosine kinases
signal transducer and activator of transcription
cytokine receptor signaling
gain-of-function mutation
tumorigenesis
ADAM17
interleukin-6
trans-signaling
epidermal growth factor receptor (EGF-R)
shedding
metalloprotease
tumor necrosis factor alpha (TNFα)
inflammation associated cancer
colon cancer
lung cancer
SH2 domain
mutations
autosomal-dominant hyper IgE syndrome
inflammatory hepatocellular adenomas
T-cell large granular lymphocytic leukemia
T-cell prolymphocytic leukemia
growth hormone insensitivity syndrome
nuclear pore complex
nuclear transport receptors
nucleocytoplasmic shuttling
targeting
tumor-associated macrophages
adoptive T cell therapy
immune suppression
STAT transcription factors
JAK
STAT
T-PLL
T-cell leukemia
meta-analysis
STAT5B signaling
small-molecule inhibitors
cancer models
companion animals
comparative oncology
pharmacological inhibitor
STAT5 signaling
chemotherapy resistance
myeloid leukemia
heat shock proteins
chaperones
stabilization
targeted therapy
ovarian cancer
hematopoietic cancers
therapeutic targeting
pharmacological inhibitors
mTOR
Bone Marrow Failure Syndromes
lymphocytes
lymphoma
T-cells
RHOA
NGS
MPN
JAK2 V617F
neoplastic stem cells
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557623503321
Moriggl Richard  
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui